Clinical trials: Adenocarcinoma of the Colon
Gastric Cancer, Gastric Adenocarcinoma
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through…
- Conditions
- Gastric Cancer, Gastric Adenocarcinoma, Gastric (Stomach) Cancer, Gastroesophageal Adenocarcinoma
- Trial name
- NCT07529808
- Testing
- BHB810
- Where
- 3 sites in United States
- Volunteers
- 164 people
- Sponsor
- BigHat Biosciences, Inc.
Colon Adenocarcinoma, Rectal Adenocarcinoma
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C.
- Trial name
- NCT06997497
- Testing
- Calderasib, Oxaliplatin, Leucovorin/levofolinate calcium
- Where
- 244 sites in United States, Argentina and 27 more
- Volunteers
- 477 people
- Sponsor
- Merck Sharp & Dohme LLC
Bladder Carcinoma, Ureter Carcinoma
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors.
- Conditions
- Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
- Trial name
- ORACLE (NCT05059444)
- Testing
- Guardant Reveal
- Where
- 57 sites in United States, France and 3 more
- Volunteers
- 2,285 people
- Sponsor
- Guardant Health, Inc.
Metastatic Colon Adenocarcinoma, Metastatic Colon Cancer
xDRIVE in Metastatic Colorectal Cancer
The study aims to evaluate the clinical utility of the xDRIVE functional precision medicine + artificial intelligence (AI) platform in predicting treatment response for metastatic colorectal cancer (mCRC).
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colon Cancer, Metastatic Rectal Adenocarcinoma, Metastatic Rectal Carcinoma
- Trial name
- NCT06929338
- Testing
- Functional precision medicine
- Sponsor
- First Ascent Biomedical Inc.
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer
- Trial name
- EVEREST-2 (NCT06051695)
- Testing
- A2B694, A2B543, xT CDx with HLA-LOH Assay
- Where
- 12 sites in United States
- Volunteers
- 474 people
- Sponsor
- A2 Biotherapeutics Inc.
Advance Solid Tumors, Colon and Rectal Cancer
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.
- Conditions
- Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC, Pancreatic Adenocarcinoma Advanced or Metastatic
- Trial name
- NCT07610798
- Testing
- INV-8989
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
Colorectal Cancer Metastatic, Adenocarcinoma of Colon
Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of an allogeneic dual-target chimeric antigen receptor natural killer (CAR-NK) cell product in adults with advanced or metastatic…
- Trial name
- NCT07462650
- Testing
- EB-DUO-CAR-NK-CEA/GCC (IV)
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Beijing Biotech
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
The goal of this study is to identify a safe and tolerated dose of the orally administered DHX9 inhibitor ATX-559. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer
- Trial name
- NCT06625515
- Testing
- ATX-559
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Accent Therapeutics
Colon Cancer Adenocarcinoma
A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer
This study is a phase Ib/II study to evaluate the efficacy, safety and tolerance of HLX43 combined with HLX07 or Serplulimab in patients with advanced or metastatic colorectal cancer failed or intolerance to standard first-line…
- Trial name
- NCT07358585
- Testing
- HLX43 dose 1 + HLX07, HLX43 dose 2 + HLX07, HLX43 dose 3 + Serplulimab
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Shanghai Henlius Biotech
Solid Tumor Cancer, Adult Refractory Cancer
Study of GV20-0251 in Participants With Solid Tumor Malignancies
This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT07070518
- Testing
- GV20-0251
- Where
- 3 sites in China
- Volunteers
- 350 people
- Sponsor
- GV20 Therapeutics
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- DENALI-1 (NCT06682793)
- Testing
- A2B395, xT CDx with HLA-LOH assay
- Where
- 10 sites in United States
- Volunteers
- 240 people
- Sponsor
- A2 Biotherapeutics Inc.
Colorectal Cancer Screening, Colorectal Cancer Metastatic
Pilot Study for Colorectal Cancer and Advanced Adenoma Detection With the Mainz Biomed Colorectal Cancer Test
The Mainz Biomed Colorectal Cancer Screening Test is being studied for its performance in the identification of the presence of colorectal cancer (CRC) or advanced adenoma (AA) in the colon in patients at average risk for…
- Conditions
- Colorectal Cancer Screening, Colorectal Cancer Metastatic, Colon Adenocarcinoma
- Trial name
- eAArly DETECT (NCT06864338)
- Where
- United States
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Mainz Biomed
Solid Tumors, Advanced Cancer
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
To assess: efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion…
- Conditions
- Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer
- Trial name
- SPARTA (NCT03175224)
- Testing
- APL-101 Oral Capsules
- Where
- 35 sites in United States, Australia and 9 more
- Volunteers
- 497 people
- Sponsor
- Apollomics Inc.
Colorectal Cancer, Colorectal Cancer Metastatic
Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy
Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Microsatellite instability or mismatch repair deficiency occurs in 20% of CRC, and is predominantly found in non-metastatic tumors.
- Conditions
- Colorectal Cancer, Colorectal Cancer Metastatic, MSI-H Colorectal Cancer, dMMR Colorectal Cancer
- Trial name
- BLOOMSI (NCT06414304)
- Where
- 2 sites in Russia
- Volunteers
- 30 people
- Sponsor
- OncoAtlas LLC
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667)…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, RET-altered Colon Cancer
- Trial name
- ARROW (NCT03037385)
- Testing
- pralsetinib (BLU-667)
- Where
- 71 sites in United States, Belgium and 11 more
- Volunteers
- 590 people
- Sponsor
- Hoffmann-La Roche
Screening for Colon Cancer, Blood Samples
Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection
The objective of this low-risk interventional study is to evaluate whether the PreveCol® test has sufficient efficiency to be considered as a second-line method for the detection of both colorectal cancer and advanced adenomas…
- Conditions
- Screening for Colon Cancer, Blood Samples, Survey and Questionnaire, Colorectal Carcinoma
- Trial name
- MS-Prevecol (NCT06703632)
- Testing
- blood sampling, Survey using a questionnaire.
- Where
- 2 sites in Portugal, Spain
- Volunteers
- 4,538 people, healthy volunteers welcome
- Sponsor
- ADVANCED MARKER DISCOVERY S.L.
Solid Tumor, Adult, Refractory Cancer
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT05669430
- Testing
- GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®]
- Where
- 13 sites in United States
- Volunteers
- 365 people
- Sponsor
- GV20 Therapeutics
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Colon Neoplasm, Colon Adenocarcinoma
Peptide-based Immunization for Colon- and and Pancreas-carcinoma
An international, multicenter study to identify tumor molecular particularities and neoepitopes among participants with colorectal and pancreatic tumors undergoing surgery.
- Conditions
- Colon Neoplasm, Colon Adenocarcinoma, Colon Cancer, Colo-rectal Cancer
- Trial name
- PICOP-GLOBAL (NCT03871790)
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- CENTOGENE GmbH Rostock